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Introduction
Monitoring patients with open-angle
glaucoma is based on the reliable
detection of early deterioration of the
visual field and subsequent lowering
of the intraocular pressure. The aim is
to prevent irreversible visual field loss
leading to visual disability (Caprioli
2008). A major problem in the assess-
ment of glaucomatous visual field pro-
gression is the lack of a gold standard
(Schulzer et al. 1991). As a conse-
quence, investigators often develop a
new method for their own purposes.
Many different methods have been
described, ranging from completely
subjective to fully automated calcula-
tions (Spry & Johnson 2002; Ernest
et al. unpublished data).
If studies are using different meth-
ods and subsequently have different
results, it is hard to distinguish the
contribution of the chosen method
from other study characteristics in the
quantification of the incidence of pro-
gression. This could make studies
incomparable to each other. However,
the extent to which the use of differ-
ent methods leads to differences in
study outcome between similar studies
has not yet been investigated. What
has been investigated is the use of dif-
ferent methods in one study popula-
tion. Most frequently, the mutual
agreement of a few methods was
investigated by studying the difference
in the proportion of patients who
develop progression and the overlap
in patients classified as having pro-
gressed. However, no studies have
been published that compare all meth-
ods in one study. Therefore, a ranking
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ABSTRACT.
Purpose: To study and quantify the difference in incidence of progression
between methods for the assessment of glaucomatous visual field progression.
Methods: We identified 2450 articles published up to April 2009 in the follow-
ing data sources: PubMed, EMBASE, and Cochrane. Ten studies covering 30
methods were included. All studies aimed to compare different methods for the
assessment of glaucomatous visual field progression in the same study popula-
tion. A network meta-analysis using a mixed-effects model was performed to
combine within-study between-method comparisons with indirect comparisons
from other studies. The summarized incidence of progression was calculated
for every method, and methods were ranked according to this incidence.
Results: In total, methods were compared in 1040 eyes of 948 patients with
glaucoma. On average, 21% of the eyes progressed. When all 30 methods
were ranked, the incidence ranged from 2% to 62%. These incidences are cor-
rected for a baseline mean deviation (MD) value of )7 decibels and a mean
follow-up time of 6 years. Besides the assessment method, the incidence was
only determined by the follow-up period and baseline MD value, leaving no
unexplained variance in the incidence of progression.
Conclusion: The incidence of progression varies considerably between different
studies. This is mainly caused by the variety of methods used to assess pro-
gression but also by differences in follow-up time and baseline visual field loss.
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of methods is missing, and it remains
unclear which methods give a high or
a low incidence of progression. The
interpretation and the possibility to
compare studies will improve with a
clear ranking. For example, it would
make a real difference to find a high
incidence with a low ranked method
when compared to finding a low inci-
dence with a high ranked method.
In this study, first, all methods to
assess glaucomatous visual field pro-
gression used in different studies were
compared. Secondly, these methods
were ranked according to their inci-
dence of progression, and their differ-
ence was quantified using a network
meta-analytic approach. Finally, we
also investigated the influence of base-
line visual field loss and follow-up
time and determined the extent to
which the incidence of progression
was explained by these variables.
Materials and Methods
Search strategy
A systematic computerized search was
performed in PubMed, EMBASE, and
all databases and registers of The
Cochrane Library, in April 2009. The
following keywords were used: (glau-
coma*) AND (prognos* OR predict*
OR progress* OR longitudinal OR
cohort OR follow-up) AND (peri-
metr* OR visual field* OR HFA OR
Octopus OR Humphrey (not in
author)). The search was limited to
articles in English, Dutch, French, or
German. A total of 2450 articles were
identified.
Selection procedure
All titles and abstracts were screened,
and articles were excluded based on
predefined exclusion criteria. Of the
remaining 782 articles that were stud-
ied completely, 48 articles fulfilled the
selection criteria (Fig. 1). The selected
studies had to follow patients with
glaucoma for minimally 1 year with
the use of conventional visual field
examinations. Studies should also
directly compare at least two methods
to assess glaucomatous visual field
progression within the same study
population. After that, the type of
perimeter used and a precise descrip-
tion of the methods used for assess-
ment of visual field progression were
recorded for these studies. In addition,
the number of participants, duration
of follow-up, number of visual field
examinations, patient characteristics,
incidence of progression, and the pub-
lication year were noted.
We combined direct and indirect
comparisons of methods in a network
meta-analysis. A direct comparison is
defined as a comparison of methods
in one study using exactly the same
study population during the same
study period. Indirect comparisons of
two methods have not actually been
made in one study but are made in
different studies by using a common
comparator (Bucher et al. 1997).
Studies were excluded when no com-
parisons with other methods in the
meta-analysis were possible. This led
to the sole inclusion of studies that
applied methods based on the Hum-
phrey Field Analyzer (HFA) (Carl
Zeiss Meditec, Dublin, CA, USA),
because this perimeter was used in
most studies on progression and no
studies were found that directly com-
pared HFA-based methods with
methods from other perimeters. Fur-
thermore, studies that did not report
incidence proportions of progression
and in which the incidence propor-
tion could not be calculated from the
data were excluded. We defined the
incidence proportion as the propor-
tion of patients with glaucoma that
developed visual field progression
during the follow-up period of a spe-
cific study. Studies with populations
that overlapped with other selected
studies were also excluded to obtain
a fair comparison between methods.
In these cases, the study was chosen
that had the most comparisons with
methods used in other studies. When
overlap of study populations was
uncertain, more information was
retrieved from the authors. Finally,
two studies were found, which inves-
tigated a selected group of patients
with glaucoma that was considered
to be progressive based on clinical
judgement (Mayama et al. 2004; Heijl
et al. 2008). These studies were
excluded, because including them
would result in selection bias (Cald-
well et al. 2005).
2450 potential relevant articles identified and screened for retrieval
48 articles fulfilled the selection criteria
Additional exclusion criteria for the meta-analysis
No Humphrey Field Analyzer (n = 8)
No reporting of incidence of progression (n = 10)
No connections with the network (n = 5)
Overlap of patients with other studies in the network (n = 10)
Pre-selected progressive patients (n = 2)
Methods were applied on different groups (n = 1)
Exclusion criteria
No measurement of visual field progression (n = 471)
Unconventional or single perimetric measurement (n = 434)
No visual field damage at baseline (n = 395)
Patients without glaucomatous disease (n = 244)
No original study (n = 172)
Follow-up of less than one year (n = 124)
Case-reports (n = 80)
Patients younger than 18 years (n = 35)
Animal study (n = 17)
Other languages than English, French, Dutch, or German (n = 8)
Abstracts (n = 23)
Article not available in the Netherlands (n = 35)
No direct comparisons between methods (n = 364)
P t ti l l t ti l  i tifi    f  t i l
12 Articles were included in the meta-analysis
A ti l  f lfill  t  l ti  it i
Fig. 1. Flow chart of the article selection process.
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Finally, the data of twelve articles
were combined in the network meta-
analysis (Fig. 1) (Birch et al. 1995;
Smith et al. 1996; Katz et al. 1997,
1999; Katz 2000; Lee et al. 2002;
Viswanathan et al. 2003; Artes et al.
2005; Nouri Mahdavi et al. 2007;
Arnalich Montiel et al. 2009; Diaz
Aleman et al. 2009; Wesselink et al.
2009). Three articles were included
that studied different methods in the
same population during the same fol-
low-up period (Katz et al. 1997, 1999;
Katz 2000). Data of these articles
were treated as a single study. The ref-
erences of all included articles were
additionally screened to identify more
studies. This did not result in addi-
tional articles. However, we found
one recent article that described the
same study as one of the included
articles (Casas Llera et al. 2009). As
additional methods were applied in
this article, we added these methods
to the meta-analysis.
Statistical analysis
If not available, incidence proportions
of glaucomatous progression were
calculated from the number of eyes
that progressed for each method
within each study. All incidence pro-
portions were then combined in a
mixed-effects model. More specifi-
cally, an arm-based network meta-
analysis model with dummy variables
to identify the various methods was
used for the analysis (Salanti et al.
2008). The computations for these
analyses were performed with the sta-
tistical software R (version 2.10.1).
An additional complication in the
analysis arose because of the fact that
incidence proportions from the same
sample using different methods are
correlated and therefore cannot be
treated as independent observations.
The magnitude of the correlation
between several incidence proportions
from the same sample can only be
calculated if a complete cross-classifi-
cation table of the various methods is
provided in an article. Usually, such
detailed information was unavailable.
We therefore used the method sug-
gested by Riley and co-workers (Riley
et al. 2008). This method substitutes
a single overall correlation parameter
for the study-specific individual corre-
lations.
The model therefore is given by:
yij¼ b1M1;ijþb2M2;ijþ :::þbxMx;ij
þ uijþ eij;
where yij is the observed incidence
proportion in study i for method j,
M1,ij is a dummy variable (i.e. coded 1
or 0), indicating whether yij corre-
sponds to method 1 (and similarly for
M2,ij through Mx,ij), the uij values
denote the random effects, and the eij
values denote the sampling errors.
The model assumes that the variances
of the uij’s are equal to s
2, denoting
the amount of heterogeneity in the
true incidence proportions. Further-
more, the correlation between two uij’s
from the same sample (i.e. study) is
denoted by q. The variances of the eij
values were estimated based on the
observed incidence proportions and
can be denoted by vij. Moreover, two
eij values from the same study are also
assumed to be related to each other
with their correlation given by q.
Finally, assuming normality of the uij
and eij values, the parameters of the
model were then estimated using
restricted maximum likelihood estima-
tion. As a result, we obtained the fol-
lowing estimates from the model: the
average incidence proportions for the
various methods (estimated values of
b1 through bx), the amount of hetero-
geneity in these results (estimate of
s2), and an estimate of the correlation
for incidence proportions arising from
the same study (estimate of q). The
precision of the estimates of b1
through bx was quantified via corre-
sponding 95% confidence intervals
obtained in the usual manner (i.e. esti-
mate of b ± 1.96 SE, where SE
denotes the standard error of the esti-
mate of b). A confidence interval was
also obtained for s2, based on a pro-
file likelihood method (Hardy &
Thompson 1996).
The mean deviation (MD) value at
baseline and the mean follow-up time
were also included as covariates in the
model, so that the incidence propor-
tions from the various methods could
be compared while controlling for the
influence of these covariates. We
included these covariates initially as
linear predictors in the model but also
examined whether the incidence pro-
portions changed as an accelerating
(quadratic) function thereof. Another
potential covariate was the mean
number of visual field examinations
for the patients in each study. How-
ever, this covariate correlated very
strongly with the mean follow-up time
in a study (r = 0.79), and therefore, it
was almost impossible to distinguish.
We chose to use follow-up time over
the number of examinations because
its influence on the incidence of pro-
gression is inherently more logical.
Where possible, we also compared
the incidence proportions of two
methods from the network model with
incidence proportions of the same two
methods, which were based only on
direct comparisons. To use a reason-
able amount of data for getting more
stable results, this additional analysis
was only performed for methods that
were directly compared in three or
more studies.
Results
The flow of articles included in this
systematic literature review is shown
in Fig. 1. Twelve articles that studied
30 methods in ten studies were
included in the meta-analysis. All
methods were named and classified in
six groups according to their main
characteristics (Table 1).
Six groups of methods
The first group consisted of methods
based on the glaucoma progression
analysis (GPA), which is similar to
the visual field endpoint in the Early
Manifest Glaucoma Trial (EMGT)
(Leske et al. 1999). We abbreviated
this group to ‘group G’, from GPA.
The GPA is an event analysis based
on pattern deviation values and is
included in the new HFA software.
When significant deterioration (p <
0.05) is seen on the pattern deviation
probability maps of the GPA print-
outs in the same three or more points
on three consecutive follow-up tests,
the software interprets this as likely
progression (Leske et al. 1999). Al-
though some studies performed sepa-
rate analyses after exclusion of eyes
with a baseline visual field ‘‘out of
range’’ according to the GPA printout
of the HFA, we used the incidences of
progression in all study eyes. Group
A (A from AGIS) consisted of two
methods that were based on the
Advanced Glaucoma Intervention
Study (AGIS) (The AGIS Inves-
tigators 1994). Both the AGIS
method and the Collaborative Initial
Acta Ophthalmologica 2012
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Glaucoma Treatment Study (CIGTS)
method, which is derived from the
AGIS method, use a scoring system to
grade each visual field in the follow-
up period. The AGIS score is based
on the actual decibel deviations at the
total deviation plot, while the CIGTS
algorithm is based on the p-values
obtained from the total deviation
probability plot. Both scoring systems
range from 0 to 20, with 0 represent-
ing no field loss and 20 end-stage dis-
ease. Visual field series are considered
to be progressive if the score has a
minimal increase of four (with the
AGIS method) or three points (with
the CIGTS method) and is confirmed
by two additional tests (Katz 1999).
In methods that are classified as
point-wise linear regression (PLR)
methods (group P from PLR), a linear
regression analysis was performed in
different individual locations at the
visual field. Another group of meth-
ods was based on a linear regression
analysis with visual field indices
(group I from indices), like the MD
and the visual field index (VFI). The
VFI is calculated by the new software
of the HFA. Each location on the
Table 1. Description of the 30 methods studied.
G Based on glaucoma progression analysis (GPA)
G1 GPA
G2 GPA using total deviation
G3 GPA with 2 follow-up visual fields
G4 Modified GPA; difference between number of improving points and deteriorating points (‡3) repeatable at 3 consecutive
examinations
G5 Modified GPA using total deviation; difference between number of improving points and deteriorating points (‡3) repeatable at 3
consecutive examinations
A Based on Advanced Glaucoma Intervention Study (AGIS) method
A1 AGIS method
A2 CIGTS method
P Based on point-wise linear regression analysis (PLR)
P1 PLR with threshold values, using a criterion of p £ 0.001 and a cut-off point of ‡4 locations
P2 PLR with threshold values, using a criterion of p £ 0.001 and a cut-off point of ‡3 locations
P3 PLR with threshold values, using a criterion of p £ 0.001 and a cut-off point of ‡2 locations
P4 PLR with threshold values, using a criterion of p £ 0.001 and a cut-off point of ‡1 location
P5 Two-omitting PLR with pattern deviation values, using criteria of £)1 dB per year and p<0.05 and a cut-off point of ‡3 locations
at 3 consecutive examinations
P6 Two-omitting PLR with total deviation values, using criteria of £)1 dB per year and p<0.05 and a cut-off point of ‡3 locations at
3 consecutive examinations
P7 PLR with total deviation values, using criteria of £ )1 dB per year and p £ 0.01 and a cut-off point of ‡3 locations at 3
consecutive examinations, with consistent worsening through the end of follow-up
P8 PLR with PROGRESSOR software (threshold values), using criteria of £ )1 dB per year and p £ 0.05 and a cut-off point of ‡2
nonedge locations
I Based on linear regression analysis with indices
I1 Linear regression analysis of a glaucoma hemifield cluster, using a criterion of p<0.005 and a cut-off point of ‡4 clusters
I2 Linear regression analysis of a glaucoma hemifield cluster, using a criterion of p<0.005 and a cut-off point of ‡3 clusters
I3 Linear regression analysis of a glaucoma hemifield cluster, using a criterion of p<0.005 and a cut-off point of ‡2 clusters
I4 Linear regression analysis of a glaucoma hemifield cluster, using a criterion of p<0.005 and a cut-off point of ‡1 cluster
I5 Linear regression analysis of the MD, using a criterion of p<0.025
I6 Linear regression analysis of the MD, using a criterion of p<0.05
I7 Linear regression analysis of the CPSD, using a criterion of p<0.025
I8 Linear regression analysis of the VFI, using a criterion of p<0.05
T Based on PLR and linear regression analysis with indices
T1 Progression according to threshold noiseless trend (TNT) program
T2 Suspected progression according to TNT program
C Based on clinical judgement
C1 Likely progression based on the subjective assessment of Humphrey printouts by multiple observers without using a predefined
criterion; observers should reach agreement and were blinded for other clinical information
C2 Likely progression based on the subjective assessment of visual fields by multiple observers using PROGRESSOR software without a
predefined criterion; observers should reach agreement and were blinded for other clinical information
C3 Nonparametric progression analysis based on nonparametric ranking of MD values
C4 At least one of these scotoma criteria: deepening of ‡2 points by ‡10 dB in the same locations; expansion of ‡2 points by ‡10 dB;
development of ‡2 adjacent points, not within or adjacent to a baseline scotoma, with p<1% or worse at the pattern deviation
plot or progression of 1 previously normal location in central 10 degrees by ‡10 dB. Confirmations at the same locations on 3
consecutive fields, based on pattern deviation values
C5 At least one of these scotoma criteria: deepening of ‡2 points by ‡10 dB in the same locations; expansion of ‡2 points by ‡10 dB;
development of ‡2 adjacent points, not within or adjacent to a baseline scotoma, with p<1% or worse at the pattern deviation
plot or progression of 1 previously normal location in central 10 degrees by ‡10 dB. Confirmations at the same locations
on 2 consecutive fields, based on pattern deviation values
Methods are classified into six groups according to their main characteristics. GPA = glaucoma progression analysis, AGIS = Advanced Glau-
coma Intervention Study, CIGTS = Collaborative Initial Glaucoma Treatment Study, PLR = point-wise linear regression, dB = decibels,
MD = mean deviation, CPSD = corrected pattern standard deviation, VFI = visual field index, TNT = threshold noiseless trend.
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visual field contributes to the VFI,
although it is more heavily weighted
to central areas of the visual field
(Bengtsson & Heijl 2008). A location
that is not significantly (p < 0.05)
depressed on the pattern deviation
probability map is considered to
have a 100% sensitivity. The VFI is
expressed as one percentage, where
100% represents a normal visual field
and 0% represents a perimetrically
blind eye. The HFA software per-
forms a linear regression analysis of
the VFI against time (Bengtsson &
Heijl 2008).
Another group of methods was
made that combined a PLR and a lin-
ear regression analysis of the MD
value. The methods in this group
(group T from TNT) were variants of
the threshold noiseless trend (TNT)
program (Gonzalez De La Rosa et al.
2009). The TNT program filters peri-
metric results and takes into account
dependency relations in the visual
field. Moreover, it combines linear
regression analyses of the MD, the
cumulative defect curve, and different
locations at the visual field. Suspected
progression is seen for the first time
that one of these parameters indicates
progression. If this result is repeated
by two consecutive examinations or if
two or more parameters indicate pro-
gression, TNT indicates definite pro-
gression (Diaz Aleman et al. 2009).
Finally, a clinical group (group C from
clinical) comprised methods based on
clinical judgement. Classified in this
group were methods based on entirely
subjective assessments of visual fields
by multiple observers, who had to
agree on progression while they were
blinded for other clinical data. Other
methods in this group used certain
algorithms for the assessment of visual
fields, for example based on the clini-
cal judgement of scotoma’s (Boden
et al. 2004). One clinical method was
based on nonparametric ranking of
MD values (Wesselink et al. 2009).
This method objectifies the commonly
practised method of monitoring glau-
coma patients with the use of MD val-
ues. A visual field series is considered
progressive as the MD value of a fol-
low-up visual field is worse than the
MD of the worse of two baseline
fields. This has to be confirmed on at
least two visual fields (Wesselink et al.
2009). We did not take into account
one subjective method that was based
on the experience and expertise of only
one observer who was not blinded for
other clinical information (Birch et al.
1995).
Population characteristics
In total, 1040 eyes of 948 patients
with glaucoma were studied in the ten
studies included. As shown in Table 2,
all patients were derived from western
countries, with mean baseline MD
values ranging from )3.3 to )10.4
decibel (dB), and mean age ranging
from 57.7 to 72.5 years. An average
of 1.7 visual fields per year were anal-
ysed in the studies. In one study,
patients received laser therapy or fil-
tration surgery according to a treat-
ment protocol (Nouri Mahdavi et al.
2007). All other patients received vari-
ous treatments during the follow-up
period. An average of six methods
was directly compared in the studies
included. The uncorrected incidence
proportions that were given or calcu-
lated for the different methods in the
studies are also shown in Table 2. The
maximum difference in the incidence
proportions within a single study was
0.44.
Ranking of methods
Figure 2 shows the ranking of the 30
methods according to their incidence
proportions when combined in the
meta-analysis. The mean estimated
incidence proportion of progression
was 0.21 (95% confidence interval
(CI) 0.15, 0.26) in 6 years (dashed
vertical line in Fig. 2), indicating that
on average 21% of the study eyes
progressed in 6 years. The incidence
proportions of progression according
to 30 methods ranged from 0.02 (CI
)0.02, 0.05) for method P1 to 0.62
(CI 0.47, 0.78) for method P8. A con-
tinuous vertical line represents the
incidence proportion of the GPA
(method G1), which was the most fre-
quently studied method, with six stud-
ies in this meta-analysis. With an
incidence proportion of 0.16 (CI 0.14,
0.19), the GPA is in the middle of the
ranking of all 30 methods. The AGIS-
based methods and most of the meth-
ods based on linear regression analysis
with indices showed lower incidence
proportions than the GPA method.
Methods that are based on clinical
judgement or the TNT program
showed higher incidences than the
GPA. All incidence proportions
shown in Fig. 2 are the estimated
rates when the mean follow-up time
was set at 6 years and the mean base-
line MD value was set at )7 dB.
These values were chosen because
these were the mean values in the ten
included studies. Follow-up time was
significantly associated with the inci-
dence of progression, with an increase
in the incidence proportion of approx-
imately 2.1 per cent points per extra
follow-up year (p < 0.001). Baseline
MD was also significantly associated
with the incidence of progression,
increasing the incidence proportion
by 0.9 per cent points per extra dB of
MD loss (p = 0.025). No accelerat-
ing (quadratic) relationships between
these two predictors and the incidence
proportions were found (p = 0.93
and p = 0.77, respectively).
Contribution of methods
The variance explained by the model
can be expressed in terms of the
amount of heterogeneity as estimated
by the model (i.e. the estimate of s2).
After correcting for follow-up time
and baseline MD, the methods used
for assessing progression accounted
for all the remaining heterogeneity
between the estimated incidences of
progression in studies (CI 0, 0.002).
To estimate the contribution of the
chosen method in the quantification
of the incidence of progression, the
model in which all methods were
assumed to have the same average
incidence of progression (without
including mean follow-up time and
MD value as covariates) was com-
pared with the model where all meth-
ods were allowed to have different
incidences. The former model yielded
an estimated amount of heterogene-
ity (i.e. the estimate of s2) equal to
0.011 (CI 0.006, 0.022), which is
decreased to 0.002 (CI <0.001, 0.008)
when all methods were allowed to
have different incidences. Therefore,
approximately 82% of the hetero-
geneity in this analysis can be acc-
ounted for by the variety of methods
used in studies. The rest of the heter-
ogeneity was explained by the mean
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All data were directly derived from the articles, but we calculated the number of visual fields per year by dividing the number of visual field examinations by the
follow-up period. * = the follow-up period for the total group of patients with glaucoma and patients with ocular hypertension was used, ** = median value,
# = data were derived from a more recent article (Casas Llera et al. 2009), which described the same study, ## = data for the total group of 221 patients was
used. MD = mean deviation, dB = decibels, NA = data not available, DIGS = Diagnostic Innovations in Glaucoma Study, GLGS = Groningen Longitudi-




We evaluated the network model with
both direct and indirect comparisons
of methods by performing an addi-
tional analysis for the direct compari-
sons only. This analysis was also
corrected for the mean follow-up time
and the mean baseline MD. Methods
G1 and G2 were the only methods
that were directly compared in three
or more studies. The estimated differ-
ence in the incidence proportion
between methods G1 and G2 was
0.081 (CI 0.043, 0.120) in the model
with only direct comparisons, while
the difference in incidence was 0.077
(CI 0.033, 0.121) in the combined
direct and indirect model. The direc-
tion and size of the difference between
methods G1 and G2 was approxi-
mately the same in the direct model as
in the combined direct and indirect
model, although the combined model
had a broader confidence interval.
Discussion
The mean incidence of glaucomatous
visual field progression that we found
in the literature was 21% in 6 years.
This incidence was based on a large
number of patients and a large num-
ber of methods to assess progression
and can be seen as an average propor-
tion of eyes that were considered to
be progressive. The incidence of visual
field progression had a large range
from 2% to 62% in 6 years, depend-
ing on the method that was used. This
again confirms the importance of the
choice of a method to assess glauco-
matous visual field progression. We
then ranked these methods according
to their incidence of progression. It is
important to note that the incidences
that we have found for each method
can only be generalized for clinically
treated glaucoma patients with a
mean baseline MD value around
)7 dB and a mean follow-up time of
6 years. The estimates of progression
should be corrected by adding 0.9%
to the incidence or by subtracting
0.9% from the incidence, for each dB
decrease and increase in baseline MD
value, respectively. In the same way,
the incidences should be corrected by
adding 2.1% for each year extra fol-
low-up. The expected incidence of
progression in an article that used
another method can thus be estimated
with the ranking presented in this
article.
Together with the range of inci-
dences of progression, we also investi-
gated to what extent the use of
different methods will lead to differ-
ences in results between studies. The
chosen method accounted for nearly
all differences in the incidence of pro-
gression that we found in the included
studies, with the exception of the part
that can be explained by the baseline
MD value and the follow-up time.
This underscores the importance of
taking account of the method used
when critically appraising and com-
paring studies on glaucomatous visual
field progression. However, the pres-
ent study also underlines the influence
of baseline visual field loss and fol-
low-up time on the incidence of glau-
comatous visual field progression.
When clinicians use the same method,
these factors are even more important



































Incidence of visual field progression 
Fig. 2. A ranking of methods is shown according to their incidence of visual field progression.
The 30 points represent the estimated incidences of progression with their 95% confidence inter-
vals of all methods studied. The incidences are corrected for a mean follow-up period of 6 years
and a baseline mean deviation value of )7 decibels. The dashed vertical line represents the
mean estimated incidence of visual field progression in the ten studies. The continuous vertical
line represents the incidence of the glaucoma progression analysis (method G1). The methods
are grouped according to their main characteristics: group G = methods based on glaucoma
progression analysis, group A = methods based on Advanced Glaucoma Intervention Study
method, group P = methods based on point-wise linear regression analysis, group I = methods
based on linear regression analysis with indices, group T = methods based on point-wise linear




in clinical practice than the method
that is used. Although a longer fol-
low-up period logically leads to an
increase in the incidence of visual field
progression, a worse baseline visual
field increases the chance of future
visual field progression in an individ-
ual patient. It has been found in pre-
vious studies that more advanced
baseline visual field loss was an inde-
pendent predictor of future visual field
progression (Leske et al. 2007). How-
ever, other studies have found a non-
linear relation of baseline visual field
and subsequent progression (Lichter
et al. 2001; Polansky et al. 2003) or
even an opposite relation (The AGIS
Investigators 2000). The latter finding
could be explained by floor effects
because of advanced visual field loss
of the AGIS patients at baseline. This
means that no worsening can be
observed when visual field loss is
already advanced, but instead even an
improvement of the visual field that is
most likely the result of regression to
the mean. With a mean baseline MD
value of )7 dB, we assume that floor
effects had no major influence on the
present results.
Although most meta-analyses use
only direct comparisons between treat-
ments or diagnostic methods, we also
used indirect comparisons. This ‘net-
work’ meta-analysis is a method to
quantify a rank order, even if no
direct comparison between two meth-
ods has been conducted. Using this
method, we made optimal use of all
available data on visual field progres-
sion in patients with glaucoma. Differ-
ences in the incidence proportions
that are found with direct compari-
sons can only be explained by the
methods that are applied, because
these comparisons are made in the
same population. In contrast, indirect
comparisons may also be influenced
by population differences. Direct com-
parisons between methods can thus be
seen as superior to indirect compari-
sons. However, in this meta-analysis,
we corrected for follow-up time and
baseline MD value, which reduced the
unexplained heterogeneity between the
incidences to zero. Therefore, we
assume that the results of our meta-
analysis provide an adequate approxi-
mation of direct comparisons between
methods that are actually only indi-
rectly compared. An additional analy-
sis using only direct comparisons
resulted in approximately the same
incidences as when both direct and
indirect comparisons were used.
Remarkably, the incidences in the
present study are much lower than the
incidences of some other well-known
studies. These studies were not
included in our meta-analysis because
they did not directly compare two or
more methods. For example, 41% of
the treated patients in EMGT pro-
gressed on their visual field in a fol-
low-up period of approximately
6 years and with a baseline MD value
of )4 dB (Heijl et al. 2002). The inci-
dence that we found for the same
method (i.e. the GPA method) was
only 16%. This large difference could
partly be explained by the frequent
testing protocol of the EMGT, in
which visual field tests were carried
out at 3-month intervals (Leske et al.
1999). Because of the two required
confirmations of the GPA method,
the availability of at least four visual
field tests per year leads to an
increased chance to detect progression
during the follow-up period. More-
over, a flexible testing protocol
resulted in even more available visual
fields in the EMGT, because addi-
tional visual field tests were performed
within 1 month when tentative progre-
ssion occurred. As shown in Table 2,
this testing frequency is much higher
than the mean frequency of 1.7 visual
fields per year in the studies that were
included in our meta-analysis. In addi-
tion, all studies in our meta-analysis
only used a fixed testing protocol or
no testing protocol. Furthermore, the
large difference could also be
explained by 61 patients in the EMGT
who had two eligible eyes for the
study. These patients had a higher
chance to be progressive because they
were considered to have progression
when the first eligible eye met the pro-
gression criteria (Heijl et al. 2002). An
additional explanation for the large
difference could be that EMGT
patients were not treated according to
current standards. For example, no
target pressure was defined for indi-
vidual patients (Leske et al. 1999). A
higher incidence of progression was
also found in the Canadian Glaucoma
Study (CGS) (Chauhan et al. 2008).
The incidence of visual field progres-
sion in this study was 31% in 5 years
in glaucoma patients with a median
baseline MD value of )4 dB. In the
CGS, a variant of method G2 was
used with a slightly stricter cut-off
point. The estimated incidence of pro-
gression of method G2 was only 24%
in our meta-analysis. In view of the
better baseline visual field and shorter
follow-up period in the CGS com-
pared with the studies in our meta-
analysis, one would just expect a
lower incidence of progression in the
CGS. However, the CGS also used a
flexible testing protocol with a testing
frequency of at least three visual fields
per year and a required confirmation
of suspected progression in 10 days
(Chauhan et al. 2008). Overall, the
studies in our meta-analysis better
reflect current clinical practice than
the above-mentioned studies. We
found incidences that are based on a
heterogeneous group of 948 patients.
The mean frequency of visual field
examinations of around 1.7 visual
fields per year in the present meta-
analysis also reflects a feasible testing
frequency in clinical practice.
Our study gives insight into the
methods that give either high or low
estimates of the incidence of glauco-
matous visual field progression but
does not solve the problem of the lack
of a gold standard. Therefore, the def-
inition of ‘true progression’ remains a
problem. A method may well result in
a high incidence proportion without
really differentiating between ‘true
progressive’ and ‘true nonprogressive’
patients. A method that correctly clas-
sifies a large proportion of the ‘true
progressive’ patients as progressive is
said to be a method with a high sensi-
tivity. On the other hand, when a
method classifies a large proportion of
the ‘true nonprogressive’ patients as
nonprogressive, it is said to be a spe-
cific method. The choice of a cut-off
point in a particular method is gener-
ally a trade-off between sensitivity
and specificity. In general, we cannot
say which method is the better one,
but we know that sensitivities and
specificities differ per method in a pre-
dictable way when another cut-off
point is used. When the cut-off value
in these methods is less strict, the sen-
sitivity increases while at the same
time, the specificity decreases. Exam-
ples in the present meta-analysis are
the PLR-based methods P1, P2, P3,
and P4, which only differ in the
number of locations that should meet
the same criterion. The criterion for
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a location to be progressive is a
statistically significant negative linear
regression line (p £ 0.001). Even with-
out looking at the results of the meta-
analysis, we can assume that method
P1, which needs the highest number
of affected locations for a visual field
series to be progressive, is the least
sensitive and the most specific. The
same holds for methods I1, I2, I3, and
I4, which differ only in the number of
progressive clusters that are required
to meet the definition of progression.
It is important to notice that in epi-
demiologic studies, methods with a
high specificity are preferred when the
true incidence of progression is low.
This leads to an estimate of the rela-
tive risk of the presumed prognostic
factor that is closer to the true value
of the relative risk. In clinical practice,
a highly specific method with few false
positives is also preferred when the
treatment of progressive patients has
considerable side-effects.
We used the results of 30 methods
in our meta-analysis, for which a
patient could only be progressive or
nonprogressive. However, some meth-
ods were originally intended to quan-
tify the rate of progression instead of
a binary presence or absence of pro-
gression. These methods are based on
indices of the complete tested visual
field such as the MD (i.e. in methods
I5 and I6) and the VFI (i.e. in method
I8). In clinical practice, the MD index
and the VFI are used to quantify the
rate of progression on a continuous
scale, ranging from severe disease pro-
gression (e.g. 16% loss in the VFI per
year) to slight improvement (e.g. 3%
increase in the VFI per year) (Bengts-
son et al. 2009). Sole statistical signifi-
cance of the slopes of these indices
may be of limited interest for clinical
practice, while knowing the rate of
progression would direct appropri-
ately aggressive treatment to those
who are at highest risk for visual dis-
ability (Caprioli 2008). However,
when a rate of progression is used to
decide on changing therapy, it has to
be decided which cut-off value for the
rate leads to the decision to change
therapy. Ultimately, even a rate
method leads to a dichotomization of
the population. Rates of progression
should therefore be incorporated in
progression criteria of methods to
determine the presence or absence of
progression. For example, progression
could be defined as a statistically
significant decline of the VFI
(p < 0.05) with a rate of at least 3%
loss per year. Several PLR methods in
the present meta-analysis (i.e. P5, P6,
P7, and P8) already used statistically
and clinically relevant criteria for indi-
vidual visual field locations. Finally,
the pattern standard deviation (PSD)
or the corrected pattern standard
deviation (CPSD) indices of the com-
plete tested visual field (e.g. in method
I7) should generally not be used in
methods to assess glaucomatous visual
field progression. Their values shift to
normal values again in more advanced
glaucoma (Heijl et al. 1987).
In conclusion, the incidence of glau-
comatous visual field progression var-
ies considerably between different
studies. This is mainly caused by the
variety of methods used to assess pro-
gression but also by differences in fol-
low-up time and baseline visual field
loss. Other factors, like the frequency
of visual field examinations and the
need for confirmation, also seem to be
of importance. With a ranking of
methods according to their incidence
of progression, the interpretation and
the possibility to compare studies are
improved. Moreover, in several cases,
the same method can be used with a
more or less specific cut-off value,
depending on the scientific or clinical
goal. An ideal method combines sta-
tistically and clinically relevant criteria
with tailor-made cut-off values.
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